{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:20:11Z","timestamp":1793974811940,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Boehringer Ingelheim Ulm University BioCenter (BIU) project TPN10."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Muscarinic Designer Receptors Exclusively Activated by Designer Drugs (DREADD) gated by clozapine-N-oxide (CNO) allow selective G-protein cascade activation in genetically specified cell-types\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Here we compare the pharmacokinetics, off-target effects and efficacy of CNO, clozapine (CLZ) and compound 21 (Cmpd-21) at the inhibitory DREADD human Gi-coupled M4 muscarinic receptor (hM4Di). The half maximal effective concentration (EC\n                    <jats:sub>50<\/jats:sub>\n                    ) of CLZ was substantially lower (0.42\u2009nM) than CNO (8.1\u2009nM); Cmpd-21 was intermediate (2.95\u2009nM). CNO was back-converted to CLZ in mice, and CLZ accumulated in brain tissue. However, CNO itself also entered the brain, and free cerebrospinal fluid (CSF) levels were within the range to activate hM4Di directly, while free (CSF) CLZ levels remained below the detection limit. Furthermore, directly injected CLZ was strongly converted to its pharmacologically active metabolite, norclozapine. Cmpd-21 showed a superior brain penetration and long-lasting presence. Although we identified a wide range of CNO and Cmpd-21 off-targets, there was hardly any nonspecific behavioural effects among the parameters assessed by the 5-choice-serial-reaction-time task. Our results suggest that CNO (3\u20135\u2009mg\/kg) and Cmpd-21 (0.4\u20131\u2009mg\/kg) are suitable DREADD agonists, effective at latest 15\u2009min after intraperitoneal application, but both require between-subject controls for unspecific effects.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-41088-2","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T08:06:06Z","timestamp":1552550766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":321,"title":["Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice"],"prefix":"10.1038","volume":"9","author":[{"given":"Martin","family":"Jendryka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Palchaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ursu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan","family":"van der Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Liss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"K\u00e4tzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Pekcec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"41088_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.neuron.2016.01.040","volume":"89","author":"BL Roth","year":"2016","unstructured":"Roth, B. L. DREADDs for Neuroscientists. Neuron 89, 683\u2013694, https:\/\/doi.org\/10.1016\/j.neuron.2016.01.040 (2016).","journal-title":"Neuron"},{"key":"41088_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuron.2009.06.014","volume":"63","author":"GM Alexander","year":"2009","unstructured":"Alexander, G. M. et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63, 27\u201339, https:\/\/doi.org\/10.1016\/j.neuron.2009.06.014 (2009).","journal-title":"Neuron"},{"key":"41088_CR3","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1073\/pnas.0700293104","volume":"104","author":"BN Armbruster","year":"2007","unstructured":"Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proceedings of the National Academy of Sciences of the United States of America 104, 5163\u20135168, https:\/\/doi.org\/10.1073\/pnas.0700293104 (2007).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"41088_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1152\/physiol.00025.2008","volume":"23","author":"Y Pei","year":"2008","unstructured":"Pei, Y., Rogan, S. C., Yan, F. & Roth, B. L. Engineered GPCRs as tools to modulate signal transduction. Physiology (Bethesda, Md.) 23, 313\u2013321, https:\/\/doi.org\/10.1152\/physiol.00025.2008 (2008).","journal-title":"Physiology (Bethesda, Md.)"},{"key":"41088_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.neuron.2006.06.018","volume":"51","author":"EM Tan","year":"2006","unstructured":"Tan, E. M. et al. Selective and quickly reversible inactivation of mammalian neurons in vivo using the Drosophila allatostatin receptor. Neuron 51, 157\u2013170, https:\/\/doi.org\/10.1016\/j.neuron.2006.06.018 (2006).","journal-title":"Neuron"},{"key":"41088_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/neuro.02.016.2009","volume":"2","author":"CD Nichols","year":"2009","unstructured":"Nichols, C. D. & Roth, B. L. Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors. Frontiers in molecular neuroscience 2, 16, https:\/\/doi.org\/10.3389\/neuro.02.016.2009 (2009).","journal-title":"Frontiers in molecular neuroscience"},{"key":"41088_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1126\/science.aan2475","volume":"357","author":"JL Gomez","year":"2017","unstructured":"Gomez, J. L. et al. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science (New York, N.Y.) 357, 503\u2013507, https:\/\/doi.org\/10.1126\/science.aan2475 (2017).","journal-title":"Science (New York, N.Y.)"},{"key":"41088_CR8","doi-asserted-by":"publisher","unstructured":"Loffler, S., Korber, J., Nubbemeyer, U. & Fehsel, K. Comment on \u201cImpaired respiratory and body temperature control upon acute serotonergic neuron inhibition\u201d. Science (New York, N.Y.) 337, 646; author reply 646 https:\/\/doi.org\/10.1126\/science.1221810 (2012).","DOI":"10.1126\/science.1221810"},{"key":"41088_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0278-5846(98)00035-9","volume":"22","author":"WH Chang","year":"1998","unstructured":"Chang, W. H. et al. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Progress in neuro-psychopharmacology & biological psychiatry 22, 723\u2013739 (1998).","journal-title":"Progress in neuro-psychopharmacology & biological psychiatry"},{"key":"41088_CR10","first-page":"243","volume":"328","author":"MW Jann","year":"1994","unstructured":"Jann, M. W., Lam, Y. W. & Chang, W. H. Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. Archives internationales de pharmacodynamie et de therapie 328, 243\u2013250 (1994).","journal-title":"Archives internationales de pharmacodynamie et de therapie"},{"key":"41088_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/jps.2600831010","volume":"83","author":"G Lin","year":"1994","unstructured":"Lin, G., McKay, G., Hubbard, J. W. & Midha, K. K. Decomposition of clozapine N-oxide in the qualitative and quantitative analysis of clozapine and its metabolites. Journal of pharmaceutical sciences 83, 1412\u20131417 (1994).","journal-title":"Journal of pharmaceutical sciences"},{"key":"41088_CR12","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1021\/acschemneuro.7b00079","volume":"8","author":"J Raper","year":"2017","unstructured":"Raper, J. et al. Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics. ACS chemical neuroscience 8, 1570\u20131576, https:\/\/doi.org\/10.1021\/acschemneuro.7b00079 (2017).","journal-title":"ACS chemical neuroscience"},{"key":"41088_CR13","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/0731-7085(96)01738-4","volume":"14","author":"G Lin","year":"1996","unstructured":"Lin, G., McKay, G. & Midha, K. K. Characterization of metabolites of clozapine N-oxide in the rat by micro-column high performance liquid chromatography\/mass spectrometry with electrospray interface. Journal of pharmaceutical and biomedical analysis 14, 1561\u20131577 (1996).","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"key":"41088_CR14","doi-asserted-by":"publisher","unstructured":"MacLaren, D. A. et al. Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments. eNeuro 3, https:\/\/doi.org\/10.1523\/eneuro.0219-16.2016 (2016).","DOI":"10.1523\/eneuro.0219-16.2016"},{"key":"41088_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22116-z","volume":"8","author":"DF Manvich","year":"2018","unstructured":"Manvich, D. F. et al. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Scientific Reports 8, 3840, https:\/\/doi.org\/10.1038\/s41598-018-22116-z (2018).","journal-title":"Scientific Reports"},{"key":"41088_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1021\/acsptsci.8b00012","volume":"1","author":"KJ Thompson","year":"2018","unstructured":"Thompson, K. J. et al. DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo. ACS Pharmacology & Translational. Science 1, 61\u201372, https:\/\/doi.org\/10.1021\/acsptsci.8b00012 (2018).","journal-title":"Science"},{"key":"41088_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.neuron.2014.04.008","volume":"82","author":"TJ Stachniak","year":"2014","unstructured":"Stachniak, T. J., Ghosh, A. & Sternson, S. M. Chemogenetic synaptic silencing of neural circuits localizes a hypothalamus\u2013\u2009>\u2009midbrain pathway for feeding behavior. Neuron 82, 797\u2013808, https:\/\/doi.org\/10.1016\/j.neuron.2014.04.008 (2014).","journal-title":"Neuron"},{"key":"41088_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1021\/cn500325v","volume":"6","author":"X Chen","year":"2015","unstructured":"Chen, X. et al. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs. ACS chemical neuroscience 6, 476\u2013484, https:\/\/doi.org\/10.1021\/cn500325v (2015).","journal-title":"ACS chemical neuroscience"},{"key":"41088_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.neuropharm.2012.05.023","volume":"66","author":"H Sanger","year":"2013","unstructured":"Sanger, H. et al. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR. Neuropharmacology 66, 264\u2013273, https:\/\/doi.org\/10.1016\/j.neuropharm.2012.05.023 (2013).","journal-title":"Neuropharmacology"},{"key":"41088_CR20","doi-asserted-by":"publisher","first-page":"19197","DOI":"10.1073\/pnas.0906593106","volume":"106","author":"JM Guettier","year":"2009","unstructured":"Guettier, J. M. et al. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proceedings of the National Academy of Sciences of the United States of America 106, 19197\u201319202, https:\/\/doi.org\/10.1073\/pnas.0906593106 (2009).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"41088_CR21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/npp.2015.229","volume":"41","author":"H Koike","year":"2016","unstructured":"Koike, H. et al. Chemogenetic Inactivation of Dorsal Anterior Cingulate Cortex Neurons Disrupts Attentional Behavior in Mouse. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 41, 1014\u20131023, https:\/\/doi.org\/10.1038\/npp.2015.229 (2016).","journal-title":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology"},{"key":"41088_CR22","unstructured":"Wilkinson, G. R. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination in Goodman & Gilman\u2019s The pharmacological basis of therapeutics 3\u201330 ((McGraw-Hill 2001)."},{"key":"41088_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/0269881103017002014","volume":"17","author":"C Greenwood-Smith","year":"2003","unstructured":"Greenwood-Smith, C., Lubman, D. I. & Castle, D. J. Serum clozapine levels: a review of their clinical utility. Journal of psychopharmacology (Oxford, England) 17, 234\u2013238, https:\/\/doi.org\/10.1177\/0269881103017002014 (2003).","journal-title":"Journal of psychopharmacology (Oxford, England)"},{"key":"41088_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.9740\/mhc.2015.03.068","volume":"5","author":"JC Ellison","year":"2015","unstructured":"Ellison, J. C. & Dufresne, R. L. A review of the clinical utility of serum clozapine and norclozapine levels. Mental Health Clinician 5, 68\u201373, https:\/\/doi.org\/10.9740\/mhc.2015.03.068 (2015).","journal-title":"Mental Health Clinician"},{"key":"41088_CR25","doi-asserted-by":"publisher","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS biology 8, e1000412, https:\/\/doi.org\/10.1371\/journal.pbio.1000412 (2010).","journal-title":"PLoS biology"},{"key":"41088_CR26","doi-asserted-by":"publisher","first-page":"e100817","DOI":"10.1371\/journal.pone.0100817","volume":"9","author":"D Delotterie","year":"2014","unstructured":"Delotterie, D., Mathis, C., Cassel, J. C., Dorner-Ciossek, C. & Marti, A. Optimization of touchscreen-based behavioral paradigms in mice: implications for building a battery of tasks taxing learning and memory functions. PloS one 9, e100817, https:\/\/doi.org\/10.1371\/journal.pone.0100817 (2014).","journal-title":"PloS one"},{"key":"41088_CR27","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3758\/brm.42.4.1059","volume":"42","author":"RN Cardinal","year":"2010","unstructured":"Cardinal, R. N. & Aitken, M. R. Whisker: a client-server high-performance multimedia research control system. Behavior research methods 42, 1059\u20131071, https:\/\/doi.org\/10.3758\/brm.42.4.1059 (2010).","journal-title":"Behavior research methods"},{"key":"41088_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nprot.2008.41","volume":"3","author":"A Bari","year":"2008","unstructured":"Bari, A., Dalley, J. W. & Robbins, T. W. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nature protocols 3, 759\u2013767, https:\/\/doi.org\/10.1038\/nprot.2008.41 (2008).","journal-title":"Nature protocols"},{"key":"41088_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.44","volume":"6","author":"AM Bygrave","year":"2016","unstructured":"Bygrave, A. M. et al. Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801. Translational psychiatry 6, e778, https:\/\/doi.org\/10.1038\/tp.2016.44 (2016).","journal-title":"Translational psychiatry"},{"key":"41088_CR30","doi-asserted-by":"publisher","first-page":"20160","DOI":"10.1073\/pnas.1214397109","volume":"109","author":"F Papaleo","year":"2012","unstructured":"Papaleo, F., Erickson, L., Liu, G., Chen, J. & Weinberger, D. R. Effects of sex and COMT genotype on environmentally modulated cognitive control in mice. Proceedings of the National Academy of Sciences of the United States of America 109, 20160\u201320165, https:\/\/doi.org\/10.1073\/pnas.1214397109 (2012).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"41088_CR31","doi-asserted-by":"publisher","first-page":"e4227","DOI":"10.1371\/journal.pone.0004227","volume":"4","author":"JW Young","year":"2009","unstructured":"Young, J. W., Light, G. A., Marston, H. M., Sharp, R. & Geyer, M. A. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PloS one 4, e4227, https:\/\/doi.org\/10.1371\/journal.pone.0004227 (2009).","journal-title":"PloS one"},{"key":"41088_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.tips.2013.04.006","volume":"34","author":"J Wess","year":"2013","unstructured":"Wess, J., Nakajima, K. & Jain, S. Novel designer receptors to probe GPCR signaling and physiology. Trends in pharmacological sciences 34, 385\u2013392, https:\/\/doi.org\/10.1016\/j.tips.2013.04.006 (2013).","journal-title":"Trends in pharmacological sciences"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41088-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41088-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41088-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T02:45:41Z","timestamp":1671245141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-41088-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["41088"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-41088-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.U., M.P., W.N. and A.P. are employees of Boehringer Ingelheim Pharma GmbH & Co. K.G. All other authors declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4522"}}